Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer

References

• Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139. doi:10.1056/NEJMoa04093815118073
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–967. doi:10.1056/NEJMoa090455419692684
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–2388. doi:10.1056/NEJMoa090953020573926
   PubMed Web of Science ®Google Scholar
• Lecia V, Sequist BAW, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Clin Cancer Res. 2011;3:1169–1180.
   Google Scholar
• Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–2247. doi:10.1158/1078-0432.CCR-12-224623470965
   PubMed Web of Science ®Google Scholar
• Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res. 2011;17(5):1169–1180. doi:10.1158/1078-0432.CCR-10-227721248300
   PubMed Web of Science ®Google Scholar
• Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol. 2013;31(31):3987–3996. doi:10.1200/JCO.2012.45.202924101047
   PubMed Web of Science ®Google Scholar
• Chong CR, Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19(11):1389–1400. doi:10.1038/nm.338824202392
   PubMed Web of Science ®Google Scholar
• Yu HA, Pao W. Targeted therapies: Afatinib–new therapy option for EGFR-mutant lung cancer. Nature Rev Clin Oncol. 2013;10(10):551–552. doi:10.1038/nrclinonc.2013.15423959269
   PubMed Web of Science ®Google Scholar
• Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC. Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res. 2011;17(11):3812–3821. doi:10.1158/1078-0432.CCR-10-340821531810
   PubMed Web of Science ®Google Scholar
• Gazdar A, Robinson L, Oliver D, et al. Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. J Thorac Oncol. 2014;9(4):456–463. doi:10.1097/JTO.000000000000013024736066
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Miller VA, Robson ME, et al. Screening for germline EGFR T790M mutations through lung cancer genotyping. J Thorac Oncol. 2012;7(6):1049–1052. doi:10.1097/JTO.0b013e318250ed9d22588155
   PubMed Web of Science ®Google Scholar
• Yu HA, Arcila ME, Harlan Fleischut M, et al. Germline EGFR T790M mutation found in multiple members of a familial cohort. J Thorac Oncol. 2014;9(4):554–558. doi:10.1097/JTO.000000000000005224736080
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.30207593
   PubMed Web of Science ®Google Scholar
• Yang Z, Yang N, Ou Q, et al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. Clin Cancer Res. 2018;24(13):3097–3107. doi:10.1158/1078-0432.CCR-17-231029506987
   PubMed Web of Science ®Google Scholar
• Wang X, Gao Y, Wang B, et al. Analytic and clinical validation of an ultrasensitive, quantitative polymerase chain reaction assay for EGFR mutation analysis with circulating tumor DNA. Arch Pathol Lab Med. 2017;141(7):978–984. doi:10.5858/arpa.2016-0083-OA28537806
   PubMed Web of Science ®Google Scholar
• Pan Y, Zhang Y, Li Y, et al. Prevalence, clinicopathologic characteristics, and molecular associations of EGFR exon 20 insertion mutations in East Asian patients with lung adenocarcinoma. Ann Surg Oncol. 2014;21(Suppl 4):S490–S496. doi:10.1245/s10434-013-3452-124419753
   PubMedGoogle Scholar
• Firmino M, Angelo G, Morais H, Dantas MR, Valentim R. Computer-aided detection (CADe) and diagnosis (CADx) system for lung cancer with likelihood of malignancy. Biomed Eng Online. 2016;15:2. doi:10.1186/s12938-015-0120-726759159
   PubMed Web of Science ®Google Scholar
• Michael F, McNitt-Gray SGAI, Charles R, et al. The Lung Image Database Consortium (LIDC) data collection process for nodule detection and annotation. Acad Radiol. 2007;14:1464–1474. doi:10.1016/j.acra.2007.07.02118035276
   PubMed Web of Science ®Google Scholar
• Jacobs C, van Rikxoort EM, Murphy K, Prokop M, Schaefer-Prokop CM, van Ginneken B. Computer-aided detection of pulmonary nodules: a comparative study using the public LIDC/IDRI database. Eur Radiol. 2016;26(7):2139–2147. doi:10.1007/s00330-015-4030-726443601
   PubMed Web of Science ®Google Scholar
• Gierada DS, Pinsky P, Nath H, Chiles C, Duan F, Aberle DR. Projected outcomes using different nodule sizes to define a positive CT lung cancer screening examination. J Natl Cancer Inst. 2014;106(11). doi:10.1093/jnci/dju061
   PubMedGoogle Scholar
• Heuvelmans MA, Walter JE, Peters RB, et al. Relationship between nodule count and lung cancer probability in baseline CT lung cancer screening: the NELSON study. Lung Cancer. 2017;113:45–50. doi:10.1016/j.lungcan.2017.08.02329110848
   PubMed Web of Science ®Google Scholar
• Chen LY, Molina-Vila MA, Ruan SY, et al. Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: a systematic review and meta-analysis. Lung Cancer. 2016;94:46–53. doi:10.1016/j.lungcan.2016.01.01926973206
   PubMed Web of Science ®Google Scholar
• Lee Y, Lee GK, Hwang JA, Yun T, Kim HT, Lee JS. Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer. Clin Lung Cancer. 2015;16(1):46–50. doi:10.1016/j.cllc.2014.09.00225450875
   PubMed Web of Science ®Google Scholar
• Lee Y, Lee GK, Lee YS, et al. Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations. Cancer. 2014;120(14):2090–2098. doi:10.1002/cncr.2871124737599
   PubMed Web of Science ®Google Scholar
• Costa C, Molina MA, Drozdowskyj A, et al. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res. 2014;20(7):2001–2010. doi:10.1158/1078-0432.CCR-13-223324493829
   PubMed Web of Science ®Google Scholar
• Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 2012;30(4):433–440. doi:10.1200/JCO.2011.38.322422215752
   PubMed Web of Science ®Google Scholar
• Fujita Y, Suda K, Fau-Kimura H, et al. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. J Thorac Oncol. 2012;7(1556–1380(Electronic)):1640–1644. doi:10.1097/JTO.0b013e3182653d7f22899358
   PubMedGoogle Scholar
• Karachaliou N, Costa C, Gimenez-Capitan A, et al. BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations. J Thorac Oncol. 2013;8(3):295–300. doi:10.1097/JTO.0b013e31827db62123407556
   PubMed Web of Science ®Google Scholar
• Zhao J, Feng H-H, Zhao J-Y, et al. A sensitive and practical method to detect the T790M mutation in the epidermal growth factor receptor. Oncol Lett. 2016;11(4):2573–2579. doi:10.3892/ol.2016.426327073519
   PubMed Web of Science ®Google Scholar
• Wu Y-L, Zhou C, Hu C-P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213–222. doi:10.1016/S1470-2045(13)70604-124439929
   PubMed Web of Science ®Google Scholar
• Attili I, Karachaliou N, Conte P, Bonanno L, Rosell R. Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. Expert Rev Anticancer Ther. 2018;18(10):1021–1030. doi:10.1080/14737140.2018.150834730079781
   PubMed Web of Science ®Google Scholar
• Jang J, Son JB, To C, et al. Discovery of a potent dual ALK and EGFR T790M inhibitor. Eur J Med Chem. 2017;136(1768):497–510. doi:10.1016/j.ejmech.2017.04.07928528303
   PubMedGoogle Scholar
• Oh JE, An CH, Yoo NJ, Lee SH. Detection of low-level EGFR T790M mutation in lung cancer tissues. Acta Pathol Microbiol Imm Scand. 2011;119(7):403–411. doi:10.1111/j.1600-0463.2011.02738.x
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958–967. doi:10.1056/NEJMoa090455419692684
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358(11):1160–1174. doi:10.1056/NEJMra070770418337605
   PubMed Web of Science ®Google Scholar
• Togashi Y, Hayashi H, Terashima M, et al. Inhibition of beta-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation. J Thorac Oncol. 2015;10(1):93–101. doi:10.1097/JTO.000000000000035325384171
   PubMed Web of Science ®Google Scholar
• Watanabe S, Yoshida T, Kawakami H, et al. T790M-selective EGFR-TKI combined with dasatinib as an optimal strategy for overcoming EGFR-TKI resistance in T790M-positive non-small cell lung cancer. Mol Cancer Ther. 2017;16(1538–8514 (Electronic)):2563–2571. doi:10.1158/1535-7163.MCT-17-035128839001
   PubMedGoogle Scholar
• Karachaliou N, Gimenez-Capitan A, Drozdowskyj A, et al. ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation. Transl Lung Cancer Res. 2014;3(2218–6751 (Print)):122–130. doi:10.3978/j.issn.2218-6751.2014.03.0225806291
   PubMedGoogle Scholar
• Furugaki K, Fukumura J, Iwai T, et al. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification. Int J Cancer. 2016;138(4):1024–1032. doi:10.1002/ijc.2984826370161
   PubMed Web of Science ®Google Scholar
• Remon J, Menis J, Hasan B, et al. The APPLE trial: feasibility and activity of AZD9291 (Osimertinib) treatment on positive plasma T790M in EGFR-mutant NSCLC patients. EORTC 1613. (1938-0690 (Electronic)).
   Google Scholar
• Santarpia M, Liguori A, Karachaliou N, et al. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer. 2017;8(1179):109–125. doi:10.2147/LCTT.S11964428860885
   PubMedGoogle Scholar
• Tan DS-W, Yang JC-H, Leighl NB, et al. Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M. J Clin Oncol. 2016;34(15_suppl):9044. doi:10.1200/JCO.2016.34.15_suppl.9044
   Web of Science ®Google Scholar
• Park K, Lee JS, Han JY, et al. 1300: efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose. J Thor. 2016;11(4):S113. doi:10.1016/S1556-0864(16)30243-X
   Web of Science ®Google Scholar
• Hashida S, Soh J, Toyooka S, et al. Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients. Oncol Rep. 2014;32(1791–2431 (Electronic)):145–152. doi:10.3892/or.2014.319724842519
   PubMedGoogle Scholar
• Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830–838. doi:10.1016/S1470-2045(15)00026-126051236
   PubMed Web of Science ®Google Scholar
• Li W, Qiu T, Guo L, et al. Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment. Cancer Lett. 2018;423(1872):9–15. doi:10.1016/j.canlet.2018.03.00529524556
   PubMedGoogle Scholar
• Wang S, Yan B, Zhang Y, et al. Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation. Int J Cancer. 2018;144:2880–2886.
   Web of Science ®Google Scholar